Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,023,908 papers from all fields of science
Search
Sign In
Create Free Account
MGCD516
Known as:
Multitargeted Kinase Inhibitor MGCD516
An orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Upon administration, multitargeted kinase…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
Broader (1)
sitravatinib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options
W. Löscher
,
H. Potschka
,
S. Sisodiya
,
A. Vezzani
Pharmacological Reviews
2020
Corpus ID: 219701056
Epilepsy is a chronic neurologic disorder that affects over 70 million people worldwide. Despite the availability of over 20…
Expand
Review
2017
Review
2017
Targeting TRK family proteins in cancer
Y. Khotskaya
,
V. Holla
,
A. Farago
,
K. R. Mills Shaw
,
F. Meric-Bernstam
,
D. Hong
Pharmacology and Therapeutics
2017
Corpus ID: 4243668
2017
2017
Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases
Anne-Sophie Cornec
,
Ludovica Monti
,
+10 authors
C. Ballatore
Journal of Medicinal Chemistry
2017
Corpus ID: 3265630
Alzheimer’s disease (AD) is a complex, multifactorial disease in which different neuropathological mechanisms are likely involved…
Expand
Review
2015
Review
2015
TRKing down an old oncogene in a new era of targeted therapy.
A. Vaishnavi
,
A. Le
,
R. Doebele
Cancer Discovery
2015
Corpus ID: 3101775
UNLABELLED The use of high-throughput next-generation sequencing techniques in multiple tumor types during the last few years has…
Expand
Highly Cited
2015
Highly Cited
2015
Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
Parag P. Patwardhan
,
K. S. Ivy
,
E. Musi
,
E. de Stanchina
,
G. Schwartz
OncoTarget
2015
Corpus ID: 7055710
Sarcomas are rare but highly aggressive mesenchymal tumors with a median survival of 10–18 months for metastatic disease…
Expand
2013
2013
In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors.
I. Papademetriou
,
C. Garnacho
,
E. Schuchman
,
S. Muro
Biomaterials
2013
Corpus ID: 206045425
2013
2013
Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells.
Yoon-Jin Lee
,
Yong-Jin Lee
,
+6 authors
Sang-Han Lee
Food and Chemical Toxicology
2013
Corpus ID: 25267367
Review
2006
Review
2006
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
M. von Mehren
Clinical colorectal cancer
2006
Corpus ID: 39443003
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal cancer of teh gastrointestinal tract. They are…
Expand
Highly Cited
2005
Highly Cited
2005
Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC)
K. Miller
,
H. Burstein
,
+7 authors
C. Baum
2005
Corpus ID: 74050868
563 Background: Autocrine and paracrine signaling involving VEGFR and PDGFR are implicated in angiogenesis and proliferation of…
Expand
Highly Cited
2000
Highly Cited
2000
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
B. Teicher
,
V. Chen
,
+4 authors
T. Amsrud
Clinical Cancer Research
2000
Corpus ID: 24533774
The scheduling of antifolate antitumor agents, including the new multitargeted autofolate LY231514 (MTA), with 5-fluorouracil was…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE